| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/23/2003 | WO2003005962A2 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 01/23/2003 | WO2003005837A1 Enteral formulations |
| 01/23/2003 | WO2002072094A3 Use of neuroactive substances and combinations thereof for the treatment of parkinsons disease |
| 01/23/2003 | WO2002066978A3 Detection of compounds that modulate inflammatory responses |
| 01/23/2003 | WO2002066509A3 Treatment involving dkk-1 or antagonists thereof |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002055152A9 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 01/23/2003 | WO2002053711A3 Use of transcription factor yb-1 in adenoviral systems |
| 01/23/2003 | WO2002051808A3 Muscarinic antagonists |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002049617A3 Self forming, thermodynamically stable liposomes and their applications |
| 01/23/2003 | WO2002048388A9 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
| 01/23/2003 | WO2002047731A3 Drug delivery compositions and coated medical devices |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002043662A3 Dietary composition containing conjugated linoleic acid and calcium for improved health |
| 01/23/2003 | WO2002038133A3 Compositions containing hydrolytically unstable compounds |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002036127A3 Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002024906A9 Induction of exon skipping in eukaryotic cells |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002019981A3 Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use |
| 01/23/2003 | WO2002017893A3 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 01/23/2003 | WO2002016553A3 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 01/23/2003 | WO2002013798A3 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002009760A3 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
| 01/23/2003 | WO2002004946A3 Methods for identifying combinations of drugs |
| 01/23/2003 | WO2002002607A3 Acid-modified arabinogalactan protein composition |
| 01/23/2003 | WO2001097856A3 An orphan nuclear receptor |
| 01/23/2003 | WO2001097843A3 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 01/23/2003 | WO2001083782A3 Novel proteases |
| 01/23/2003 | US20030018987 Animal model for use in the diagnosis and treatment of eating, apoptosis and infectious disorders |
| 01/23/2003 | US20030018084 Beta-adrenergic blockade reversal of catabolism after severe burn |
| 01/23/2003 | US20030018079 Treatment |
| 01/23/2003 | US20030018078 Glaucoma treatments with reduced hyperpigmentation |
| 01/23/2003 | US20030018061 Novel remedies with the use of beta 3 agonist |
| 01/23/2003 | US20030018049 Azithromycin combination for emesis control in mammals |
| 01/23/2003 | US20030018043 N-methylnalorphine |
| 01/23/2003 | US20030018031 Formulations of 5HT agonists |
| 01/23/2003 | US20030018027 Methods and pharmaceutical compositions for preventing problem behaviors of companion animals |
| 01/23/2003 | US20030018019 Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| 01/23/2003 | US20030018008 Synergistic mixture of adenosine antagonist and antiserotonine agent |
| 01/23/2003 | US20030017998 Alzheimer's disease; Parkinson's disease |
| 01/23/2003 | US20030017995 Dialysis solutions and methods |
| 01/23/2003 | US20030017991 Substrates and assays for beta-secretase activity |
| 01/23/2003 | US20030017989 Use of angiotensin I derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| 01/23/2003 | US20030017986 Topical administering bactericide and permeable adjustment protein |
| 01/23/2003 | US20030017977 Methods of treating inflammatory skin diseases |
| 01/23/2003 | US20030017975 Immunosuppressants; activation of lipopeptide fungicides |
| 01/23/2003 | US20030017972 Drug delivery |
| 01/23/2003 | US20030017969 Methods and pharmaceutical compositions for healing wounds |
| 01/23/2003 | US20030017966 MC4-R as target for the identification of compounds used to treat drug addiction |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017586 Nucleotide sequences coding polypeptide for use in the treatment of viral diseases |
| 01/23/2003 | US20030017533 Slo2 and Slo4, novel potassium channel proteins from human brain |
| 01/23/2003 | US20030017532 ndp |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017520 High-efficiency assay for protein mannosyl transferases |
| 01/23/2003 | US20030017512 Angiostatin receptor |
| 01/23/2003 | US20030017502 Methods involving the use of capG as a diagnostic marker and methods for the identification of capG modulators for the treatment and prevention of osteoporosis and related disease states |
| 01/23/2003 | US20030017479 Methods for the detection, treatment, and prevention of neurodegeneration |
| 01/23/2003 | US20030017478 Collection of prokaryotic DNA for two hybrid systems Helicobacter pylori protein-protein interactions and application thereof |
| 01/23/2003 | US20030017468 Nucleotide sequences which code lung preferential gene for use in the treatment and diagnosis of lung cancer |
| 01/23/2003 | US20030017218 Soft tissue anticancer agents |
| 01/23/2003 | US20030017215 Soft tissue anticancer agents |
| 01/23/2003 | US20030017207 Compositions and methods for treating vulvovaginitis and vaginosis |
| 01/23/2003 | US20030017206 Negatively charged amphiphilic block copolymer as drug carrier |
| 01/23/2003 | US20030017181 Including one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid |
| 01/23/2003 | US20030017177 Topical application of compositions containing an alkanolamine such as ethylaminoethanol, methylaminoethanol |
| 01/23/2003 | US20030017166 Combination preparation for the therapy of immunological diseases |
| 01/23/2003 | US20030017164 Dye-azide compounds for dual phototherapy |
| 01/23/2003 | US20030017160 Human checkpoint kinase, hCDS1, compositions and methods |
| 01/23/2003 | US20030017155 Treating a condition characterized by activation of the inflammatory cytokine cascade |
| 01/23/2003 | US20030017153 Determining whether a patient's immune system can be modified through stimulation of thymus function; sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. |
| 01/23/2003 | US20030017151 Receptor Activator of NF-kappa B antagonists; treatment of medical conditions that require the formation of new bone. |
| 01/23/2003 | US20030017150 Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses |
| 01/23/2003 | US20030017147 Novel alpha-2-antiplasmin- binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient |
| 01/23/2003 | US20030017145 Treating subjects suffering from herpes virus infections, acquired immunodeficiency syndrome, and hepatitis C infections by administering a compound effective to inhibit the production or release of the ROMs. |
| 01/23/2003 | US20030017130 A hydroxycarboxylic acid is present in the form of a free acid, lactone, or salt and a retinoid in stereoisomeric or non-isomeric form |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2821544A1 Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease |
| 01/23/2003 | CA2454135A1 Gpcs as modifiers of the irrtk and p21 pathways and methods of use |
| 01/23/2003 | CA2453784A1 A core formulation |
| 01/23/2003 | CA2453474A1 Vegfr-1 antibodies to treat breast cancer |
| 01/23/2003 | CA2453470A1 Use of follistatin for the treatment of hepatic fibrogenesis |
| 01/23/2003 | CA2453403A1 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | CA2453399A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | CA2453340A1 .beta.-adrenergic blockade reversal of catabolism after severe burn |
| 01/23/2003 | CA2453309A1 Peptide for regulation of tissue plasminogen activator |
| 01/23/2003 | CA2453175A1 Interaction inhibitors of tcf-4 with beta-catenin |